培米加替尼

培米加替尼（CAS 1513857-77-6）的公开数据库记录，列此仅供独立核对。

这个物质在各数据库里的编号

数据库记载的用途

• Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. It is also indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
• Pemigatinib is a fibroblast growth factor (FGF) receptor kinase inhibitor that is used to treat unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma, as well as myeloid or lymphoid neoplasms with FGFR rearrangements. Pemigatinib is associated with transient and usually mild-to-moderate elevations in serum aminotransferase levels during therapy, but has not been convincingly linked to cases of clinically apparent liver injury with jaundice.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Pemigatinib is approved to treat adults with:
• • Cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery. It is used in patients whose cancer has already been treated and has an FGFR2gene fusion or other change in the structure of the FGFR2 gene.¹
• • Myeloid or lymphoid cancer that has come back or did not respond to treatment and has a certain change in the structure of the FGFR1 gene.

它在各数据库里的别名

Pemigatinib; 1513857-77-6; Pemazyre; INCB054828; Fgfr inhibitor INCB054828; Y6BX7BL23K; INCB-054828; DTXSID501027955; pemigatinibum; RefChem:58318; DTXCID401513523; Pemigatinib [INN]; Pemigatinib [USAN]; INCB54828; INCB-54828; UNII-Y6BX7BL23K

计算机算出的分子描述符

数据库摘要

Pemigatinib · CAS 1513857-77-6 · C24H27F2N5O4. UNII Y6BX7BL23K.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。